2014
Does tadalafil prevent erectile dysfunction in patients undergoing radiation therapy for prostate cancer?
Publication
Publication
Asian Journal of Andrology , Volume 16 - Issue 5 p. 664- 665
A recently published paper addressed the interesting topic of prevention of erectile dysfunction (ED) with tadalafil, a phosphodiesterase-type 5 inhibitor (PDE5i) in patients undergoing radiation therapy for localized prostate cancer. <sup>[1]</sup>Tadalafil 5 mg or placebo was administered once-daily for 24 weeks in patients undergoing external-beam radiotherapy (EBRT) or brachytherapy (BT) for prostate cancer. This randomized trial did not show superior efficacy of the active drug compared with placebo 4-6 weeks after stopping the study drug. Furthermore, patients younger than 65 years did not respond significantly better than older patients.
| Additional Metadata | |
|---|---|
| doi.org/10.4103/1008-682X.133324, hdl.handle.net/1765/84255 | |
| Asian Journal of Andrology | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Incrocci, L. (2014). Does tadalafil prevent erectile dysfunction in patients undergoing radiation therapy for prostate cancer?. Asian Journal of Andrology, 16(5), 664–665. doi:10.4103/1008-682X.133324 |
|
